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A unique collaboration revolutionises the 
pharmaceutical sector in Ireland  
Short summary of the impact
Pharmaceutical manufacturing contributes 
vitally to Ireland’s economy: it employs 
over 25,000 individuals directly and 24,500 
indirectly, and produces over 50% of all 
exports, making Ireland the second-largest 
pharmaceutical exporter in the world  . 
However, the sector faces several global 
challenges: the emergence of lower-cost 
economies; the ‘patent cliff’; and the rise 
of generic medicines. It has also suffered 
from a lack of cohesion between research 
and industry and poor fundamental 
understanding of certain pharmaceutical 
manufacturing processes. The Synthesis 
& Solid State Pharmaceutical Centre 
(SSPC) has collaborated with industry to 
optimise these pharmaceutical processes, 
enabling Ireland to confront many of the 
global challenges above. Resulting gains in 
productivity have saved tens of millions of 
euros for Ireland’s pharmaceutical industry. 
Additional impacts include job creation 
and retention; a broad collaborative 
network for sharing expertise; greener 
manufacturing processes. Ireland is 
becoming a global hub of pharmaceutical 
process innovation and advanced 
manufacturing. 
Underpinning research
Pharmaceutical solids are manufactured 
via a series of chemical synthesis steps 
followed by a number of unit operations, 
which involve processing solids, including 
crystallisation, drying, milling, granulation 
and tableting. These operations establish 
key properties of the pharmaceutical solids 
that affect downstream processing and 
eventual bioavailability.
Fundamental research by the SSPC 
significantly increased the sector’s 
capability to produce pharmaceutical 
solids with predefined characteristics, 
including crystalline or amorphous 
composition, particle size, habit and 
morphology, tensile strength, powder 
flow and release properties. Previous 
work on crystallisation in bulk chemicals 
by University of Limerick (UL) researchers 
(Hodnett & Frawley) and Aughinish 
Alumina sowed the seeds for the SSPC 
collaboration (funded by >€1 million from 
Marie Curie Transfer of Knowledge 2004-
2007 [RA 11]). Based on the significant 
success of this collaboration, UL (Hodnett 
& Shire) suggested applying crystallisation 
research within the pharmaceutical sector. 
Potential collaborators were open to this 
idea as the UL academics had a track 
record of working well with both industry 
and other academic institutions and were 
seen as capable of delivering solutions 
within parallel industries. 
As such, UL has been central to creating 
a dialogue with industry. From the 
beginning, the research has been critically 
informed by the needs of the pharma end-
users, including: Pfizer, Eli Lilly, Glaxo Smith 
Kline, Janssen, Merck, Roche, Bristol Myers 
Squibb, UCB Pharma, and Clarochem 
Ireland Ltd. Each academic collaborator 
to the SSPC has contributed specific 
techniques and expertise: the University 
of Limerick (UL) brought Physical Property 
Science, Polymorphism, Chemical 
Engineering, Modelling and Computational 
Fluid Dynamics (CFD); University College 
Cork (UCC), Synthetic Organic Chemistry 
and Solid State Properties; University 
College Dublin (UCD), Chemical 
Engineering; Trinity College Dublin (TCD), 
Pharmaceutics, Spray-Drying and Milling; 
and National University of Ireland Galway 
(NUIG), Analytics and Chemometrics. 
From the outset, the collaboration has 
been uniquely inclusive and equitable; 
all research monies are shared among 
partners, and all industry and academic 
members have an equal voice. 
At its formation, the SSPC’s remit 
comprised 13 individual projects scheduled 
to run over 4-5 years. During this time, 
the SSPC successfully leveraged funding 
for an additional 11 PhD students, 
(€1,000,000) from a number of sources 
including the Irish Research Council 
(IRC), SFI, UL and industry, and added 14 
projects to its portfolio. Over time, the 
research programme consolidated into 
three key strands of research: process 
crystallisation, particle engineering, and 
active pharmaceutical ingredient (API)/
formulation interface. 
  
In the period from 2007-2012 the SSPC 
received over €10.8 million in funding 
from SFI/Industry (RA 7 to 10); as a further 
testament to its research, an additional 
€31 million award (RA 6) allowed the SSPC 
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to become a full research centre in 2013, 
with a core operations team (8), principal 
investigators (10), funded investigators (17), 
post-doctoral research associates (30), and 
PhD students (60). In lay terms, successful 
collaboration in the crystallisation space 
gave SSPC members (and funders) the 
confidence to expand their focus to cover 
the entire pharmaceutical process, from 
molecule to medicine. In the 12 months 
since becoming a fully-fledged research 
centre, the SSPC has added a further 
€8,459,272 (RA 1 to 5) to its portfolio. This 
brings the SSPC’s total funding to over €60 
million; this has come primarily through 
grants from Science Foundation Ireland 
(SFI) and industry.
Dissemination
Early on, the SSPC identified key journals 
and high-impact conferences in which to 
publish and disseminate research results, 
leading to significant collaborative output 
in terms of publication and dissemination 
activities. The key outputs include over 
145 publications in high-impact research 
journals (e.g. Refs 1 to 6), many of which 
are used daily by researchers in industry 
and are cited extensively (>150 for top 
8 publications since the first paper was 
published in 2009). 
The SSPC’s research has been presented 
to over 250 academic audiences nationally 
and internationally. In addition, the SSPC 
has hosted two conferences: in 2012, the 
10th International Workshop on Crystal 
Growth of Organic Materials; and in 
October 2013, its inaugural flow chemistry 
conference in the area of continuous 
processing. The 2013 conference was 
attended by leading industrialists and 
academics from around the world, 
marking the SSPC as an emerging leader 
in the field. Additionally, the conference 
has led to engagement with SK Korea, 
Astra Zeneca, and corporate Research & 
Development headquarters of all existing 
industrial partners; Astra Zeneca is now 
represented on the SSPC Governance 
committee. Subsequent to this conference, 
Prof. Hodnett was invited to contribute to a 
White Paper on continuous crystallisation 
which was presented in MIT in May 2014. 
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Details of the impact
Professional Communities of Practice
The SSPC has created a consortium 
of industry and academic partners in 
Ireland which is the most inclusive and 
collaborative pharmaceutical/academic 
partnership in the world. To support this 
collaboration, the SSPC laid a strong 
foundation for communication and 
information sharing by developing a 
number of key web portals, including:
1. The Best Practice Crystallisation (BPX) 
website (http://www.bpx.ie), which is the 
world’s first pharmaceutical best-practice 
portal for crystallisation. The BPX portal has 
over 16,000 web-users, with over a quarter 
of a million page views since September 
2007. Over 50% of its registered members 
coming from outside Ireland (EU, United 
States, and the rest of the world), and 
it boasts over 500 active members in 
industry and academia. Pfizer has made 
this site an integral part of their Global R&D 
training regime for researchers. Minister 
for Enterprise, Trade and Employment 
1    http://www.een-ireland.ie/eei/assets/documents/uploaded/general/Pharmaceuticals%20Fact%20sheet.pdf 
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Mary Coughlan TD, when launching 
the BPX portal, commented that “(this) 
development…enables unprecedented 
collaboration among a range of industrial 
and academic partners…in the field of 
pharmaceutical compound crystallisation.”
2. Access to Third Level Analytical 
Services (ATTLAS, http://www.attlas.ie), 
which provides a ‘one-stop-shop’ for 
the pharmaceutical industry; it details 
all facilities, equipment and analytical 
services available across all Irish higher 
education institutions (HEI’s), including 
over 230 individual pieces of equipment 
incorporating 92 analytical techniques 
that can address over 160 industry-related 
problems. With over 50,000 page views 
and 43,000 web users, ATTLAS is widely 
cited as a resource for industry and 
academia alike . ATTLAS was launched 
by Irish Minister for Finance Michael 
Noonan TD; Science Foundation Ireland, 
the government funding body for science 
research, stated, “We need to support this 
important industry in Ireland and we more 
than have the collective capability to do so, 
as ATTLAS now clearly indicates.”
Capacity building
In addition to its academic outputs, the 
SSPC has engaged in extensive capacity 
building through education and training. 
SSPC academics designed and ran 17 
bespoke training courses across Ireland, 
attended by over 2,000 participants, 
focusing on crystallisation and other 
challenges facing the pharmaceutical 
industry. 92% of participants rated these 
workshops excellent, commenting: 
“Communication was excellent”; “Very 
clear course content”; “Case studies were 
a great idea; “Interactive and thought 
provoking”. As a result, companies 
across Ireland have changed their batch 
manufacturing instructions (effectively 
altering drug manufacture “recipes”), 
leading to improved quality and reduced 
costs. 
For example, Company A has been able to 
design 7/10 new crystallisation processes, 
which increased their parent company’s 
confidence in their R&D capacity. The 
company stated that a key benefit of 
SSPC collaboration was “tailored training 
programmes on crystallisation for our 
chemists and engineers”. This provided a 
deeper understanding of the crystallisation 
2    http://siliconrepublic.com/innovation/item/27503-third-level-sector-target ; http://www.independent.ie/business/irish/cluster-to-boost-drug-industry-
research-1428065.html ; http://www.biotechnologyireland.com/pooled/articles/BF_NEWSART/view.asp ; http://www.digitalcrew.ie/index.cfm/page/newsarchive/id/3 ; 
http://pmbrc.org/index.php/equipment-and-capabilities ; and http://www.sfi.ie/investments-achievements/research-showcase/solid-state-pharmaceuticals-cluster/ 
process which had heretofore never been 
achieved. 
Reciprocal training of researchers, with 
more than 20 three-month PhD student 
placements in industry, has led to further 
knowledge exchange and capacity building 
within the SSPC. Training and reciprocal 
knowledge transfer allowed Company B 
to improve one particular crystallisation 
process, leading to savings of millions of 
euros. This shifted the perception of that 
company in the eyes of its corporate HQ 
thereby allowing it to tender internally for 
more ambitious projects thereafter. As a 
result, Company B attracted new product 
development and production, which 
would not have occurred without the 
specialised knowledge developed through 
their partnership with the SSPC. 
Training and development of scientists 
has led to impressive career progression 
for SSPC PhD graduates: while 20% of 
graduates remain in academia upon 
graduation, 80% obtain employment in 
industry. Such movement into industry 
significantly exceeds both national and 
university averages: nationally 32.3% of 
PhD graduates find work in industry, with 
46.7% of PhD graduates remaining in 
academia .
One of the SSPC’s main successes, 
which is difficult to quantify, is in the 
precompetitive collaborative research 
space. The SSPC has demonstrated 
an unparalleled ability to create an 
environment where potentially competing 
industry partners are comfortable 
working with each other and with 
academics in areas of common interest. 
This environment has been created 
over a very short timeframe through the 
aforementioned activities, structures and 
communication platforms. “The SSPC 
was identified as a benchmark model for 
collaboration – it was seen as an example 
of what has worked well in Ireland, having 
a critical mass of world-class people, and 
delivering value for money.” Dr. Michael 
Napier, Scientific Fellow, Global Technical 
Services, Janssen.
Economic impact
The SSPC’s research and activities have 
given rise to a broad range of economic 
gains (Sources 1 to 9). All 17 companies in 
the consortium (including 7 of the world’s 
leading pharmaceutical companies) note 
that SSPC membership offers a wide 
variety of ongoing economic impacts. 
Company C significantly telescoped 
an 11-step manufacturing process, 
demonstrating to its parent company 
that the Irish plant was able to solve 
complex development challenges and 
provide institutional support far exceeding 
its previous capabilities. Company D 
noted that “the joint SSPC-Company D 
crystallisation project led to tens of millions 
of savings for our company”. Company E 
had a 20% failure rate in a seeded cooling 
crystallisation process due to polymorphic 
issues; after troubleshooting by an SSPC 
PhD student, the company saw no failures 
in subsequent years, and benefited from 
“a greater companywide understanding of 
the crystallisation process… with significant 
commercial upside.” Company F stressed 
the commercial/economic benefits of the 
partnership: “We have worked closely with 
SSPC on a number of projects since 2007. 
This collaboration has led to optimisation 
of the crystallisation of three products, 
delivering more consistent manufacturing 
processes.”
Job creation is a significant metric for 
industrial/academic collaborations 
globally. The SSPC has significantly 
contributed to job retention and creation 
in the Irish pharmaceutical sector. 
Company B claims that “the direct 
economic impact of SSPC has been the 
retention of 400 high value jobs in Ireland.” 
Company G states that SSPC membership 
was key to a successful takeover by a 
larger conglomerate: “Access to ideas and 
knowledge from other companies and 
academia was the deal maker for the sale.” 
In addition to enabling member companies 
to create and retain jobs, the SSPC in 
UCD (Glennon & Barrett) created a spin-
out company, APC Ltd., which provides 
contract pharmaceutical research services. 
APC Ltd. currently employs more than 
30 people and has delivered solutions on 
over 80 projects globally .  The company 
has had significant commercial benefit for 
the consortium; as one company noted, 
“We can now take on development work 
which we could not before, as we have the 




As a result of the SSPC’s effectiveness, 
Irish policy makers have placed its work 
on the national agenda by designating 
pharmaceutical processing and drug 
delivery as a research priority area 
(therapeutics) (Sources 1 to 9). On 
launching the SSPC as a research centre, 
Minister for Jobs, Enterprise and Innovation 
Richard Bruton TD noted that we are 
“creating a magnet where we can bring 
even more research excellence to Ireland 
and create a driver for this sector. ”These 
sentiments were echoed by Minister for 
Research & Innovation Seán Sherlock TD, 
who stated that further funding of the 
SSPC was seen as a “smart investment for 
the future that transcends 5-year, 10-year 
horizons.” 
In summary, the work of the SSPC is 
transforming the Irish pharmaceutical 
industry. Ireland’s pharmaceutical sector 
is no longer purely manufacturing-based; 
it is becoming a specialist R&D resource, 
able to solve complex problems in a broad 
range of pharmaceutical manufacturing 
processes.
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Dr Mary Shire, Vice President Research, Michael Noonan, Minister for Finance, Prof Don Barry, UL President, 
Jan O’Sullivan, Minister for Education at the launch of SSPC. 
Find out more: Watch the video at 
www.ul.ie/researchimpact
This case study was authored by Patrick Frawley, Sarah Hayes, 
Kieran Hodnett and Jon O’Halloran.
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